Localized pancreatic cancer, reportedly diagnosed in 9% of patients, is associated with a 26% 5-year survival. Distant stage disease at diagnosis is associated with only a 15% 1-year and 2% 5-year survival [1]. Given the poor prognosis, accurate staging is essential and pivotal to patient management decisions that are decided through a multidisciplinary approach [5]. Imaging plays a critical role in pancreatic cancer staging and therapeutic decision process. The imaging armamentarium used to evaluate pancreatic cancer includes multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and fluorine-18-2-fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET)/CT. aPrincipal Author, University of Texas MD Anderson Cancer Center, Houston, Texas. bResearch author, University of Texas MD Anderson Cancer Center, Houston, Texas. cPanel Chair, Johns Hopkins University School of Medicine, Baltimore, Maryland. dMemorial Sloan Kettering Cancer Center, New York, New York; American College of Surgeons. eUniversity of Arizona, Banner University Medical Center, Tucson, Arizona. fMontefiore Medical Center, Bronx, New York. gColumbia University, New York, New York; American Gastroenterological Association. hUniversity of Florida College of Medicine, Gainesville, Florida. iNew York University Medical Center, New York, New York. jNorthwestern University, Chicago, Illinois. kUniversity of Texas MD Anderson Cancer Center, Houston, Texas. lUniversity of Alabama Medical Center, Birmingham, Alabama. mThe Warren Alpert School of Medicine at Brown University, Providence, Rhode Island. nUniversity of Illinois College of Medicine, Chicago, Illinois; American College of Physicians. oSpecialty Chair, University of Washington, Seattle, Washington. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels.
Staging of Pancreatic Ductal Adenocarcinoma. Localized pancreatic cancer, reportedly diagnosed in 9% of patients, is associated with a 26% 5-year survival. Distant stage disease at diagnosis is associated with only a 15% 1-year and 2% 5-year survival [1]. Given the poor prognosis, accurate staging is essential and pivotal to patient management decisions that are decided through a multidisciplinary approach [5]. Imaging plays a critical role in pancreatic cancer staging and therapeutic decision process. The imaging armamentarium used to evaluate pancreatic cancer includes multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and fluorine-18-2-fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET)/CT. aPrincipal Author, University of Texas MD Anderson Cancer Center, Houston, Texas. bResearch author, University of Texas MD Anderson Cancer Center, Houston, Texas. cPanel Chair, Johns Hopkins University School of Medicine, Baltimore, Maryland. dMemorial Sloan Kettering Cancer Center, New York, New York; American College of Surgeons. eUniversity of Arizona, Banner University Medical Center, Tucson, Arizona. fMontefiore Medical Center, Bronx, New York. gColumbia University, New York, New York; American Gastroenterological Association. hUniversity of Florida College of Medicine, Gainesville, Florida. iNew York University Medical Center, New York, New York. jNorthwestern University, Chicago, Illinois. kUniversity of Texas MD Anderson Cancer Center, Houston, Texas. lUniversity of Alabama Medical Center, Birmingham, Alabama. mThe Warren Alpert School of Medicine at Brown University, Providence, Rhode Island. nUniversity of Illinois College of Medicine, Chicago, Illinois; American College of Physicians. oSpecialty Chair, University of Washington, Seattle, Washington. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels.